Introduction：Basic information about CAS 263707-16-0|ESI 09, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | ESI 09 |
|---|
| CAS Number | 263707-16-0 | Molecular Weight | 330.76900 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C16H15ClN4O2 | Melting Point | / |
|---|
| MSDS | USA | Flash Point | / |
|---|
Names
| Name | 3-Isoxazolepropanenitrile, α-[2-(3-chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-β-oxo- |
|---|
| Synonym | More Synonyms |
|---|
ESI 09 BiologicalActivity
| Description | ESI-09 is a novel noncyclic nucleotide EPAC antagonist with IC50 values of 3.2 and 1.4 μM for EPAC1 and EPAC2, respectively. |
|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Cancer |
|---|
| Target | IC50: 3.2 μM (EPAC1), 1.4 μM (EPAC2)[1] |
|---|
| In Vitro | While cAMP competes with 8-NBD-cAMP binding with an IC50 of 39 µM, ESI-09 shows an increased potency with an apparent IC50 of 10 µM. ESI-09 inhibis cAMP-mediated EPAC2 and EPAC1 GEF activity with an IC50 of 1.4 and 3.2µM, respectively. ESI-09 could fit well into the functional cAMP-binding pocket of EPAC1, establishing favorable hydrophobic and hydrogen bonding interactions with the protein’s active-site residues. ESI-09 inhibits 007-AM-stimulated Akt phosphorylation at T308 and S473 in a dose-dependent manner. ESI-09 inhibits pancreatic cancer cells AsPC-1 and PANC-1 migration. ESI-09 inhibits EPAC1-mediated adhesion of PDA cells on collagen I[1]. Exposure to ESI-09 significantly reduces intracellular and total bacterial counts in HUVECs at 30 min postinfection with 10 multiplicities of infection (MOI) of R. australis compared with similarly infected controls[2]. |
|---|
| In Vivo | Treatment with ESI-09 dramatically protects WT mice against R. australis infection with much milder disease manifestations and significantly improves survival[2]. |
|---|
| Cell Assay | INS-1 cells are plated in 96-well plates precoated with polylysine. After overnight incubation, the medium is replaced with Krebs-Ringer bicarbonate (KRB) containing 2.9 mM glucose. After an additional 2-hour incubation, the cells are treated with ESI-09 or DMSO vehicle as a control in fresh KRB containing 11.8 mM glucose for 10 minutes, followed by a 30-minute stimulation with 10 µM 007-AM. The supernatant is collected, and insulin is quantified using an Ultra Sensitive Rat Insulin ELISA kit from Crystal Chem Inc[1]. |
|---|
| Animal Admin | Mice: ESI-09 is dissolved in buffered saline containing 10% (vol/vol) ethanol and 10% (vol/vol) Tween-80. Thirty-three WT C57BL/6 mice are divided into four groups [11 mice (group A), 10 mice (group B), 6 mice each (groups C and D)]. Groups A and C are treated with the Epac-specific inhibitor ESI-09 [10 mg/kg ] via i.p. injection for 5 d before infection, whereas groups B and D are treated with vehicle, followed by i.v. inoculation of R. australis for groups A and B or mock inoculation for groups C and D. ESI-09 or vehicle treatment is continued for another 7 d until mice are killed on day 8. During the course of the experiments, animals are monitored daily for signs of illness and mortality[2]. |
|---|
| References | [1]. Almahariq M, et al. A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. Mol Pharmacol. 2013 Jan;83(1):122-8. [2]. Gong B, et al. Exchange protein directly activated by cAMP plays a critical role in bacterial invasion during fatal rickettsioses. Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19615-20. |
|---|
Chemical & Physical Properties
| Molecular Formula | C16H15ClN4O2 |
|---|
| Molecular Weight | 330.76900 |
|---|
| Exact Mass | 330.08800 |
|---|
| PSA | 91.28000 |
|---|
| LogP | 3.87288 |
|---|
| InChIKey | DXEATJQGQHDURZ-UHFFFAOYSA-N |
|---|
| SMILES | CC(C)(C)c1cc(C(=O)C(C#N)=NNc2cccc(Cl)c2)no1 |
|---|
| Storage condition | -20℃ |
|---|
Safety Information
| RIDADR | NONH for all modes of transport |
|---|
Synonyms
